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The new international guidelines for the diagnosis and management of hypertension 
proposed higher thresholds for the diagnosis of hypertension in patients with higher 
cardiovascular risk, such as patients with diabetes, chronic kidney disease, and the 
elderly. The premise for the new recommendations was the results of randomized 
clinical trials, such as the ACCORD trial. Nonetheless, the results of the ACCORD 
trial were within the predicted by the meta-analysis of risk and confirmed by meta-
analysis of clinical trials, particularly for stroke. The decision to use 140 mmHg 
as the therapy goal would be to deny diabetic patients the benefit of preventing 
a large proportion of strokes. In addition, the meta-analysis conducted in the 
United States did not address prehypertension, ignoring many trials performed 
with patients presenting prehypertension and cardiovascular disease, showing the 
benefit of further lowering blood pressure. The guidelines recommended angiotensin 
receptor blockers as one of the first options for all patients and particularly patients 
with diabetes and chronic kidney disease. Three recently published meta-analyses 
and review showed that these agents are practically inert in the prevention of all-
cause death and cardiovascular events. In conclusion, there is evidence showing 
that hypertension should be more aggressively prevented and treated, and that 
angiotensin receptor blockers should not be the first option to start the treatment.
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 International guidelines for the diagnosis and management of 
hypertension were recently released1,2. A historical trend of lowering blood 
pressure (BP) thresholds to diagnose hypertension in high-risk individuals 
was unexpectedly reversed. BP targets for the treatment were modified 
accordingly. Therefore, some individuals who were hypertensive before 
are now normotensive. Other guidelines still recommend the previous 
diagnostic limits and goals of treatment3-5, resulting that one individual 
may be hypertensive in some countries and normotensive in others. The 
guidelines are more homogeneous in the recommendations for treatment, 
particularly in regard to the liberal options of drugs to start the treatment. 
This open recommendation includes drugs without unbiased evidences 
of effectiveness, such as Angiotensin Receptor Blockers (ARBs). In 
this point of view, I discuss the reasons and misconceptions concerning 
the establishment of diagnostic thresholds and the shortcomings in the 
recommendations of antihypertensive drugs.
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What are the thresholds to diagnose 
hypertension?
The guidelines of the European Society of 
Hypertension and European Society of Cardiology 
were the first to recommend new thresholds for the 
diagnosis of hypertension. According to them, the 
target values in the treatment of hypertension in 
patients with diabetes were set at 140/85 mmHg1 
instead of 130/80 mmHg, as recommended by 
the previous guidelines6. In addition, the new 
guidelines recommended that drug treatment 
should be started at BP higher than 160 mmHg in 
elderly patients. 
The European guideline is sometimes 
confusing, referring to diagnostic thresholds and 
to goals of treatment in other tables. For instance, 
the recommendations for elderly patients are 
contradicted in the next recommendation, which 
states that antihypertensive drug treatment may also 
be considered in the elderly (at least when younger 
than 80 years) when systolic blood pressure (SBP) 
is in the 140–159 mmHg range, provided that 
antihypertensive treatment is well tolerated. Since 
BP-lowering drugs are well tolerated, it is possible 
to assume that we should start treating patients 
at lower BP levels (140 mmHg, as in the previous 
guideline), since it is impossible to know a priori if 
the patient will tolerate the treatment.
The Eighth Joint National Committee (JNC 
8) report2 presented a radical shift from the (JNC 
7)7. The report addressed only drug treatment, 
excluding the overall evaluation of the patient, 
methods of BP measurement, strategies to 
diagnose identifiable causes of secondary 
hypertension, lifestyle recommendations, and 
other aspects related to the overall management 
of hypertension. In regard to diagnostic thresholds 
and goals of treatment, the (JNC 8) was clearer than 
the European guidelines, and did present higher 
diagnostic values for BP in some conditions as well. 
For non-elderly adults, the report maintained 
140/90 mmHg as diagnostic of Hypertension and 
also as a goal of treatment. For individuals over 60 
years, the report established 150 mmHg of systolic 
BP as the new diagnostic limit and the target of 
treatment, keeping 90 mmHg for diastolic BP. The 
most radical modification, however, was in patients 
with diabetes and chronic kidney disease (CKD). 
The current recommendations are the same as 
those for adults without diabetes (140/90 mmHg), 
in comparison with 130/80 mmHg recommended 
in the JNC 7 report. The JNC 8 report did not 
address prehypertension, a condition proposed in 
the JNC 7 and that is a current focus of research, 
both in terms of risk for cardiovascular disease and 
therapeutic approach.
The guidelines from the National Institute for 
Health and Clinical Excellence (NICE) were issued 
in 20113. This guideline was the first to include out-
of-office BP measurement, either by Ambulatory 
Blood Pressure (ABP) monitoring or Home Blood 
Pressure (HBP) monitoring, as additional criteria 
to diagnose hypertension. The algorithms are 
more complex, but the office BP was set at 140/90 
mmHg for adults younger than 80 years old, with or 
without diabetes or CKD.
The current Brazilian guidelines were not 
updated recently and are still similar to the 
previous European guidelines4. The recently 
released recommendations from the Brazilian 
Ministry of Health5 maintain 130/80 mmHg as the 
treatment target in patients with diabetes, CKD, 
high cardiovascular risk, and secondary prevention 
of stroke.
Where do we stand in face of the paradoxical 
changes in the major guidelines and the differences 
between guidelines? Should we follow the new 
recommendations or should we keep a more 
aggressive approach to lower BP, particularly in 
patients with higher cardiovascular risk? I believe 
that the reasons to establish new thresholds were 
not fully revised and that it is necessary to take in 
consideration the full set of evidence to support our 
decisions.
The authors of the American and the European 
guidelines based their new target recommendations 
for BP treatment on the results of randomized 
clinical trials (RCT). They should be complimented 
by the initiative, which recognizes the primacy of 
the results of RCT to justify medical decisions. 
Nonetheless, they misinterpreted the results of 
the ACCORD trial8. Moreover, they left aside the 
results of many trials that were done with patients 
with normal BP, assuming that these trials were 
not applicable to patients with hypertension. We 
had the opportunity to deeply discuss these and 
other issues related to goals of treatment and the 
J-shaped phenomenon9. In summary, I present 
below the main points that support my view.
The wrong interpretation of the ACCORD trial
The ACCORD study tested the hypothesis 
that lowering blood pressure beyond guidelines 
recommendations would confer higher 
cardiovascular protection8. The trial assessed the 
incidence of cardiovascular events in patients 
with diabetes assigned to intensive therapy, 
targeting a systolic pressure of less than 120 
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mm Hg, as compared with the standard therapy, 
targeting a systolic pressure of less than 140 
mm Hg. The incidence of the primary endpoint, 
coronary heart disease events, was not statistically 
different between treatment arms, and serious 
adverse events were three times more frequent 
in the intensive arm. Therefore, the experts 
recommended 140/90 mmHg as the goal in the 
management of hypertension for patients with 
diabetes. Nonetheless, there are sound evidence-
based reasons to dissent from this view and to 
recommend low blood pressure targets to prevent 
cardiovascular disease.
Strategy trials, such as the ACCORD trial, are 
less susceptible to confounding than cohort studies, 
but are not fully free of potential confounding. 
Reasons include the possibility that BP reduction 
in a proportion of patients treated intensively and 
the interruption of drug treatment at lower BP levels 
could be harmful. The results of the ACCORD trial 
were within the predicted by the meta-analysis of 
risk10 and confirmed by the meta-analysis of clinical 
trials11. There was a 13% reduction in the incidence 
of coronary artery disease, in comparison with 
22% predicted by the meta-analysis of clinical 
trials (figure 1). It is noteworthy that the estimate 
of the meta-analysis was based in 71 studies 
with 9,811 events, in comparison with 126 events 
of the ACCORD trial. For stroke, the relative risk 
reduction in the ACCORD trial was identical to that 
predicted by the meta-analysis of 45 studies, with 
5,420 events (figure 1). It is of note the magnitude 
of the benefit, a relative risk reduction of 41%. The 
absolute incidence of stroke in the ACCORD trial 
was unexpectedly low. Taking into account the 
higher incidence of stroke in our country, and its 
devastating consequences, the decision to use 
140 mmHg as the goal of therapy would be to deny 
diabetic patients the benefit of preventing a large 
proportion of strokes.
Figure 1: Relative risk for coronary heart disease and stroke in blood pressure-difference trials, in 
epidemiological studies and in the ACCORD trial. Reproduced, with permission, from reference 11.
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Table 1: Clinical trials showing the effectiveness of blood pressure-lowering drugs in the prevention of cardiovascular 
events in patients with normal blood pressure.
RRR: relative risk reduction
* In individuals aged at least 55 with another major cardiovascular risk factor (elevated cholesterol levels, low HDL-cholesterol, cigarette 
smoking, or microalbuminuria).
MI: myocardial infarction; CV: cardiovascular
# estimate for the entire cohort, not significantly different between normotensive and hypertensive individuals
Clinical condition References Active treatment
Primary 
outcome
RRR
(95% CI)
Diabetes mellitus* 13 Ramipril MI, stroke or CV 
death
25%
(12 to 36)
Any evidence of atherosclerosis in 
the coronary, cerebral, or peripheral 
territories
14
15
Ramipril
Perindopril
MI, stroke or CV 
death
MI, CV death or 
cardiac arrest
22%
(14 to 30)#
20%
(9 to 29)#
Recovered from stroke 16 Indapamide plus 
perindopril
Stroke 42%
(19 to 58)
Asymptomatic heart failure 17 Enalapril CV deaths 12%
(-3 to 26)
Overt heart failure 18
19
Enalapril
Captopril
CV deaths 18%
(6 to 28)
21%
(5 to 35)
The benefit of treating patients with low blood 
pressure in patients with subclinical or clinical 
disease
Previous trials done in patients with clinical 
or subclinical cardiovascular disease (heart 
failure, stroke, myocardial infarction, evidence 
of atherosclerosis, and diabetes) demonstrated 
significant reduction of cardiovascular events 
with the use of blood pressure lowering agents 
independently of baseline blood pressure12. Table 
1 presents the results of the more representative 
studies13-19. The benefit of treatment was mostly 
attributed to blood pressure-independent effects 
of the agents tested in these studies, the so-called 
pleiotropic effects. Nonetheless, the intensity of 
blood pressure reduction itself could explain the 
benefits of treatment. The meta-analysis by Law 
and co-authors11 demonstrated that the prevention 
of coronary artery disease and stroke with further 
reduction of blood pressure was independent of its 
values at the beginning of these trials (figure 2). 
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Figure 2: Relative risks for coronary events and stroke in patients stratified by blood pressure at the beginning of 
randomized controlled clinical trials. Reproduced, with permission, from reference 11.
There is a proof of the concept that high blood 
pressure is the major risk of for cardiovascular 
disease20. The magnitude of the benefit in clinical 
trials regarding the control of high BP was within the 
estimations of risk provided by cohort studies. For 
a reduction of 10 mmHg in systolic or 5 mmHg of 
diastolic blood pressure, the relative risk reduction 
of coronary heart disease was 22% (95% CI from 
27 to 17%) in a meta-analysis of clinical trials, close 
to the estimation of reduction of 25% (23 to 27%) 
provided by a meta-analysis of cohort studies. The 
corresponding values for stroke were 41% (33 to 
48%) in clinical trials compared to a cohort risk 
prediction of 36% (34 to 38%)20.
Besides the risks of prehypertension for 
cardiovascular disease, it is a precursor of full 
hypertension in high proportion of individuals. Many 
studies have identified the cardiovascular risks of 
prehypertension and the incidence of hypertension 
21-24. In Porto Alegre, four in five individuals from 
40 to 49 years old with prehypertension became 
hypertensive in 10 years25. Studies examining 
the benefit of drug treatment in patients with 
prehypertension free of cardiovascular disease 
are warranted26, as the PREVER-prevention 
trial, a nationwide RCT on the way in Brazil27. 
The PREVER-prevention trial enrolled about 700 
participants, who are being followed for 21 months. 
In the meantime, it is worthy to present the option 
to start low doses of BP agents for individuals 
with prehypertension without co-morbidities who 
do not respond to the prescription of lifestyle 
modification28.
Taken together, these pieces of evidence 
support the view that most guidelines moved to 
the wrong direction. Evidence still do not show 
the whole picture, and should be accompanied 
for indirect evidences and findings in analogous 
models to build the theory. If someone wants to live 
more than 100 years, he or she should keep blood 
pressure below 120 by 80 mmHg, which are the BP 
values of worldwide centenarians.
Misleading indications to start drug treatment
This is another sensitive issue. I strongly 
disagree with the recommendations of all guidelines 
to employ ARBs as a one of the first options for 
all patients and particularly with the preference 
to use these drugs in patients with diabetes and 
CKD. I have challenged this recommendation in 
manuscripts and letters about this topic in the last 
14 years, and it seems that I may be right. Let’s see 
a summary of the evidence or lack of evidence.
ARBs are among the worldwide leading 
brands of blood pressure-lowering agents. This 
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Figure 3: Relative risks and 95% confidence intervals for the occurrence of cardiovascular outcomes in clinical 
trials comparing ARBs with other drugs or placebo in patients with hypertension or high cardiovascular risk; 
the outcomes were the primary outcome of the studies or a co-primary or secondary outcome with significant 
difference between the trial arms (references in the text). Reproduced, with permission, from reference 39.
preference, endorsed by guidelines, is based on 
their neutral or beneficial metabolic effects, and 
on putative cardiac and renal protective effects 
independent of their blood pressure-lowering 
effect – the pleiotropic effects. The corporate bias, 
allied with a massive commercial promotion, may 
explain part of this preference29. Large clinical 
trials designed to demonstrate such effects, mostly 
comparing ARBs with placebo on top of the usual 
treatment, have failed to demonstrate additional 
cardiovascular protection by ARBs and suggested 
that they may be associated with worse renal 
outcomes30-38. I reviewed the results of the major 
clinical trials where an ARB was compared with an 
active treatment or placebo39. The only study where 
an ARB was superior to the comparator in the 
prevention of cardiovascular outcomes in patients 
with hypertension or at high cardiovascular risk 
was the LIFE trial30. Nonetheless, atenolol was an 
inadequate comparator40, and more patients on 
losartan used diuretics41. Figure 3 summarizes the 
risks for major cardiovascular outcomes in studies 
that compared ARBs with other agents and with 
placebo.
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Putative cardiac and renal pleiotropic effects of 
ARBs are the basis for their preferential indication 
to prevent the recurrence of atrial fibrillation and to 
protect the kidney. The evidence comes mostly from 
experimental studies, placebo-controlled trials, 
and from a post-hoc analysis of the flawed LIFE 
trial. New findings are casting doubt upon these 
preferential indications for ARBs. The efficacy of 
ARBs in the prevention of atrial fibrillation was not 
confirmed by four large studies specifically designed 
to investigate this outcome36,42-44. At least six large 
studies with ARBs suggest that these agents may 
have adverse effects over the kidneys, particularly 
when used together with angiotensin converting 
enzyme (ACE) inhibitors. In the RASS study45, a 
complex but well-designed trial in patients with 
type 1 diabetes and normoalbuminuria, the 5-year 
cumulative incidence of microalbuminuria was 6% 
in the placebo group, 4% in the enalapril group, 
and 17% with losartan (P=0.01). The addition of 
telmisartan to ramipril in order to get dual blockade 
of the renin-angiotensin axis in the ONTARGET 
trial46 was associated with an increase of 33% in 
the incidence of renal impairment (P<0.001) and 
a trend for higher rate of renal dialysis (P=0.10). 
The ROADMAP trial37 reported a higher reduction 
in glomerular filtration rate in patients treated with 
olmesartan instead of placebo. In the ACTIVE 
trial36 the incidence of renal dysfunction leading 
to discontinuation of the drug almost doubled in 
patients treated with irbesartan. In the TRANSCEND 
trial33, the decrease in glomerular filtration rate was 
greater with telmisartan than with placebo.
Three meta-analysis of RCT that compared 
ARBs with active or placebo comparators showed 
that they were inert in the prevention of total 
mortality and major cardiovascular outcomes. The 
first explored the efficacy of ARBs in the prevention 
of myocardial infarction and other cardiovascular 
outcomes47. Patients had various criteria for 
enrollment in the trials, such as hypertension, 
heart failure, diabetes, stroke, atrial fibrillation, 
and others. In total, 37 randomized clinical trials, 
with 147 020 participants, were included. When 
compared with placebo or active treatment, ARBs 
were inert in the prevention of myocardial infarction 
(relative risk 0.99, 95% confidence interval 0.92 
to 1.07), death, cardiovascular death, or angina 
pectoris.
The second meta-analysis investigated the 
efficacy of Renin–Angiotensin–Aldosterone 
System (RAAS) inhibitors over cardiovascular 
morbidity–mortality trials48. The trials should have 
at least two-thirds of the patients diagnosed 
with hypertension. The cohort included 158,998 
patients. RAAS inhibition was associated with a 5% 
reduction in all-cause mortality (HR: 0.95, 95% CI: 
0.91–1.00), and a 7% reduction in cardiovascular 
mortality (HR: 0.93, 95% CI: 0.88–0.99). The effect 
was entirely due to ACE inhibitors (HR: 0.90, 95% 
CI: 0.84–0.97). ARB treatment had no effect in the 
prevention of all-cause mortality (HR: 0.99, 95% 
CI: 0.94–1.04).
A more recent meta-analysis presents another 
piece of concern about the status of ARB in the 
prevention of cardiovascular disease49. This meta-
analysis was restricted to patients with diabetes. 
Compared to placebo or other active treatment, in 
23 studies with 32,827 diabetic patients, angiotensin 
converting enzyme inhibitors (ACEIs) significantly 
reduced the risk of all-cause mortality by 13% (RR, 
0.87; 95%CI, 0.78-0.98) and CV deaths by 17% 
(0.83; 0.70-0.99). ACE inhibitors were effective 
in the prevention of major CV events, myocardial 
infarction and heart failure. In contrast with the 
effectiveness of ACEIs, ARBs were ineffective to 
reduce the risk for all-cause mortality (RR, 0.94; 
95%CI, 0.82-1.08) in 13 studies with placebo or no 
treatment control, with a total of 23,867 patients. 
With the exception of a reduction in the risk of heart 
failure, ARBs were ineffective in the prevention of 
CV death rates (1.21; 0.81-1.80) and major CV 
events (0.94; 0.85-1.01). According with the results 
of this meta-analysis, the preference for an ARB 
may be denying diabetic patients the benefit of 
treatment. The number needed to treat with an 
ACEi to prevent one death is approximately eight. 
Since ARBs did not prevent all-cause deaths, 
choosing an ARB would be associated with a risk 
of one death for every eight patients treated with 
an ARB instead of an ACEi (NNK (number needed 
to kill )= 8).
Besides these frustrating findings in meta-
analyses and large clinical trials, several studies on 
ARBs are under legal scrutiny. Three studies were 
retracted from the literature because of scientific 
fraud50-52. A former director of Novartis Pharma’s 
scientific affairs department was recently arrested 
on suspicion of falsifying clinical data to overstate 
the benefits of the Swiss drug manufacturer’s 
hypertension drug valsartan53. These disclosures 
led to the replacement of the president and two 
other senior executives of the Japanese subsidiary 
of Novartis.
The PREVER treatment trial is the first 
large double-blind RCT that is comparing an 
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ARB (losartan) with an association of diuretics 
(chlorthalidone and amiloride)54. The trial enrolled 
about 700 patients, who are being followed for 21 
months. The outcomes are blood pressure and 
target organ damage: glomerular filtration rate, 
microalbuminuria, and left ventricular hypertrophy 
estimated by ECG. Results are planned for the end 
of this year.
It's almost inexplicable how ARBs have reached 
the leadership in the preference of physicians to 
treat hypertension and prevent cardiovascular 
disease, in face of this overwhelming volume of 
evidence demonstrating that they are probably 
inert or have minor effects in the prevention of 
cardiovascular disease. The corporate bias, 
defined as the distortions in the planning, 
presentation or interpretation of RCT that favor the 
drugs from the sponsor of the RCT29, has surely 
an influence. But more than the legitimate interest 
of corporations to sell their products, scientists 
in the field of hypertension, who are the authors 
of guidelines, had a critical role in promoting the 
benefits of these drugs. The results of individual 
and large RCT were mostly negative, but the 
scientists in the field of cardiovascular prevention 
in patients with hypertension and diabetes favored 
the results of small and sometimes biased RCTs, 
most of them looking at the effects on surrogate 
endpoints, and the findings from the overwhelming 
number of experimental studies in animal models. 
The agenda for the investigation of diagnostic 
and therapeutic methods for the diagnosis and 
prevention of cardiovascular disease cannot be left 
only to the discretion of the big-Pharm55. Scientists 
should preserve their independence and work for 
the universities who pay their salaries.
conclusion
High blood pressure plays a key role in the 
development of cardiovascular disease and should 
be more aggressively prevented and treated than 
the recommended by current guidelines. The 
preference for angiotensin receptor blockers is not 
supported by evidences and may deny patients the 
benefits of proved blood pressure-lowering agents. 
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